Testosterone Enanthate
- Generic Name
- Testosterone Enanthate
- Brand Names
- Delatestryl, Xyosted
- Drug Type
- Small Molecule
- Chemical Formula
- C26H40O3
- CAS Number
- 315-37-7
- Unique Ingredient Identifier
- 7Z6522T8N9
- Background
Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate. This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule. This testosterone derivative was first approved on December 24, 1953.
...
- Indication
⑴男性性功能低减替代疗法；⑵绝经后女性晚期乳腺癌姑息性治疗；⑶男性青春期发育迟缓。⑷再生障碍性贫血。
- Associated Conditions
- Congenital Hypogonadotropic Hypogonadism, Hypergonadotropic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism
- Associated Therapies
- -
Working Out M0 Bipolar Androgen Therapy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-18
- Target Recruit Count
- 69
- Registration Number
- NCT06594926
- Locations
- 🇦🇺
St Vincents Hospital, Darlinghurst, New South Wales, Australia
🇦🇺GenesisCare North Shore, St Leonards, New South Wales, Australia
🇦🇺Sydney Adventist Hospital, Wahroonga, New South Wales, Australia
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-04-15
- Target Recruit Count
- 21
- Registration Number
- NCT04460872
- Locations
- 🇺🇸
Brooks Rehabilitation, Jacksonville, Florida, United States
🇺🇸North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
- Conditions
- Interventions
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 150
- Registration Number
- NCT04363164
- Locations
- 🇺🇸
Dana-Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Testosterone Effects on Pelvic Floor Muscles
- Conditions
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Brigham and Women's Hospital
- Registration Number
- NCT04026880
Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 36
- Registration Number
- NCT03516812
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Testosterone and rHGH in FSHD
- Conditions
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT03123913
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Pennington Biomedical Research Center
- Target Recruit Count
- 53
- Registration Number
- NCT02734238
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
- Conditions
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02697188
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, United States
🇺🇸dgd Research, Inc, San Antonio, Texas, United States
Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2020-11-06
- Target Recruit Count
- 222
- Registration Number
- NCT02286921
- Locations
- 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸SKCCC at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.